Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic...
Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
Site Reference ID/Investigator# 61282, Detroit, Michigan, United States
Site Reference ID/Investigator# 52122, San Antonio, Texas, United States
Site Reference ID/Investigator# 51463, Lebanon, New Hampshire, United States
Site Reference ID/Investigator# 49952, Madison, Wisconsin, United States
Site Reference ID/Investigator# 49953, Tucson, Arizona, United States
Site Reference ID/Investigator# 51403, Tacoma, Washington, United States
Vanderbilt Cool Springs, Franklin, Tennessee, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.